Nurtec ODT (rimegepant ODT) / Pfizer - LARVOL DELTA

Comparison of Rimegepant and Placebo for Pain in IBS (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed

Trial completion • Gastrointestinal Disorder • Pain

Exploring the Potential Dermatological Benefits of CGRP Inhibition: A Case Report. (PubMed, J Drugs Dermatol) - "The patient was prescribed rimegepant, a CGRP receptor antagonist, for migraine management...2025;24(6):636-637. doi:10.36849/JDD.8880."

Journal • Acne Vulgaris • CNS Disorders • Dermatology • Inflammation • Migraine • Pain • Polycystic Ovary Syndrome • Rosacea

Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. (PubMed, J Headache Pain) - No abstract available

Journal • Review • CNS Disorders • Migraine • Pain

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Tumor mutational burden • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (clinicaltrials.gov) - P3 | N=723 | Recruiting | Sponsor: Pfizer | Trial completion date: Nov 2026 ➔ Mar 2027

Trial completion date • CNS Disorders • Migraine • Pain

Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review. (PubMed, Pain Manag) - "A comprehensive search of PubMed/MEDLINE and ClinicalTrials.gov was conducted to identify phase-3, placebo-controlled trials of gepants (atogepant, rimegepant), anti-CGRP mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab), and traditional treatments (propranolol, topiramate, onabotulinumtoxinA). Anti-CGRP/R medications present a more favorable benefit/risk ratio than traditional treatments. These findings, combined with individual patient histories and preferences, can inform clinical decision-making."

Journal • Review • CNS Disorders • Migraine • Pain

The Potential of ROR1 as a Novel Therapeutic Target for Endometriosis (WCE 2025) - "Of these, cabergoline (a dopaminergic agonist), pirenzepine (an antimuscarinic and PARP inhibitor), and rimegepant (CGRP antagonist for migraine nociception) were prioritised and tested in a ROR1-expressing adherent cell line and patient-derived organoids. Conclusion ROR1 is a promising target for precision endometriosis treatment due to its upregulation in endometriosis lesions and low expression in adult tissues. Investigating ROR1-targeting therapies is warranted, including the repurposing of migraine drug rimegepant, which may exert nociception effects while also preventing endometriosis lesion growth through ROR1 inhibition."

CNS Disorders • Endometriosis • Gynecology • Migraine • Oncology • Pain • Women's Health • ROR1

The R-E-V-I-V-A-L Study (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P2 trial • CNS Disorders • Migraine • Pain

Acute Migraine Treatment in the ED With Gepants (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: Icahn School of Medicine at Mount Sinai

New P4 trial • CNS Disorders • Migraine • Pain

Rimegepant in airplane headache treatment: a case report. (PubMed, J Med Case Rep) - "This novel use of rimegepant, typically employed in migraine management, demonstrates a promising therapeutic option for airplane headache."

Journal • CNS Disorders • Migraine • Mood Disorders • Pain • Psychiatry

Induction of more severe central sensitization in a medication overuse headache model mice through active ingestion of rizatriptan. (PubMed, J Headache Pain) - "This study pioneers an ethologically valid MOH model that reflects more severe central sensitization and recapitulates active medication-seeking behaviour. PrL-mediated addiction-like-behaviour pathways and SPVC-centred nociceptive processing may play roles in the development of MOH. These findings provide novel neuromodulation targets (PrL, IC, SPVC) for refractory MOH management."

Journal • Preclinical • CNS Disorders • Migraine • Mood Disorders • Pain • Psychiatry • FOS

Comparative proteomics and structure-based approach to unravel the therapeutic drug target of Theileria species. (PubMed, J Genet Eng Biotechnol) - "Virtual screening revealed FDA-approved drugs (i.e. atogepant and rimegepant) as promising compounds, showing the highest affinity for SfiIp during molecular docking. Further studies, including molecular dynamics simulation, principal component analysis, and free energy landscape, suggested that these drug molecules exhibit the stable interaction with protein. Therefore, our research could facilitate the identification and targeting of novel drug candidates that may be further implemented to recognize effective therapeutics against Theileria infections."

Journal • Infectious Disease

Cost-effectiveness Analysis of Zavegepant in Acute Migraine Treatment (ISPOR 2025) - "Zavegepant is cost-effective compared with rimegepant for the acute treatment of migraine under the threshold of $100,000 per QALY gained."

Cost effectiveness • HEOR • CNS Disorders • Migraine • Pain

Comparative Risk of Major Adverse Cardiovascular Events among Patients who Initiate Treatment with Acute Migraine Agents (ISPOR 2025) - "Our study found that ubrogepant and rimegepant were associated with a lower risk of MACE compared to sumatriptan highlighting their potential as safer alternatives for patients with cardiovascular risk. No significant difference in MACE risk was observed between lasmiditan and sumatriptan suggesting the need for further research to better understand the cardiovascular safety profile of lasmiditan."

Adverse events • Clinical • Cardiovascular • CNS Disorders • Migraine • Myocardial Infarction • Pain

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. (clinicaltrials.gov) - P3 | N=775 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine • Pain

Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical study. (PubMed, Pain Manag) - No abstract available

Journal • CNS Disorders • Migraine • Pain

A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase classification: P1 ➔ P2 | N=20 ➔ 240

Enrollment change • Phase classification • CNS Disorders • Migraine • Pain

Comparison of Rimegepant and Placebo for Pain in IBS (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Disorder • Pain

C4951003: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Pfizer | Trial completion date: Jun 2027 ➔ Jul 2030 | Trial primary completion date: Jun 2027 ➔ Jul 2030

Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain • Pediatrics

Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. (PubMed, J Headache Pain) - "CGRP has multiple and often potentially opposing effects on the immune system. In effect, preventive CGRP pathway antagonists (especially eptinezumab and galcanezumab) possibly only mildly increase the risk of infections. However, it is unlikely to affect most migraine patients considering relatively high NNH, low effect size and few infectious SAEs reported so far. The result of CGRP-targeting therapies potentially depends on the type of pathogen and patient's immune status. Consequently, in immunocompromised patients or at public health levels the increased infection risk may have more pronounced effect."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Infectious Disease • Migraine • Pain

Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system. (PubMed, Expert Opin Drug Saf) - "Galcanezumab showed strong signals for underdose (ROR 47.4; 95% CI 43.79-51.3), alopecia (5.72; 5.09-6.43), and constipation (6.01; 5.35-6.75), while fremanezumab exhibited notable associations with alopecia (6.9; 5.72-8.33) and weight increased (6.34; 5.18-7.76). Among gepants, rimegepant was linked to somnolence (4.52; 3.57-5.73) and dizziness (3.73; 3.15-4.42) and atogepant showed a strong signal for therapy interruption (16.58; 12.86-21.38). This study highlights CGRP inhibitor-associated AEs, underscoring the need for clinical monitoring and risk identification. Early detection of AEs and SDRs can inform protective measures to enhance patient safety."

Adverse events • HEOR • Journal • Real-world evidence • Alopecia • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Migraine • Pain

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance (Pfizer Press Release) - "First-quarter 2025 operational revenue reflected higher revenues primarily for: Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 33% operationally, driven largely by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets....Comirnaty globally, up 62% operationally, driven primarily by higher revenues in the U.S. reflecting lower expected returns and higher market share, as well as higher contractual deliveries in certain international markets....Nurtec ODT/Vydura globally, up 40% operationally, driven primarily by strong demand in the U.S. and favorable changes in channel mix and, to a much lesser extent, recent launches in certain international markets."

Sales • Amyloidosis • Infectious Disease • Novel Coronavirus Disease

Pharmacology in Pain Management Workshop (APS 2025) - "Explore current insights into migraines, from neurological mechanisms to innovative therapies like Rimegepant. Finally, tackle clinician burnout with practical solutions to sustain your passion and elevate patient care. This workshop promises to equip you with knowledge, empowerment, and strategies to build your resilience in healthcare."

CNS Disorders • Migraine • Pain • Sleep Disorder

Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. (PubMed, J Headache Pain) - "The study highlights the rapid uptake of rimegepant in Denmark, especially among middle-aged females with a history of triptan use and medication overuse. While rimegepant was associated with a reduction in acute medication overuse, early discontinuation rates suggest barriers to sustained use, potentially influenced by cost, efficacy, or patient preferences. There is a need for strategies to optimize long-term adherence and access to rimegepant in clinical practice."

Journal • CNS Disorders • Migraine • Pain